血糖控制与CYP3A5基因多态性对成人肾移植后他克莫司谷浓度的影响
该回顾性观察队列研究纳入42例接受控释他克莫司口服的成人肾移植受者,评估HbA1c水平与他克莫司药代动力学的关系。多因素线性回归显示,治疗6个月后影响他克莫司C/D比值升高的因素为男性性别和CYP3A5非表达者(r=.59,P<.001),12个月后为HbA1c水平升高和CYP3A5非表达者(r=.62,P<.001)。CYP3A5非表达者中12个月时C/D比值与HbA1c呈正相关(y=54.6x-194.6,r=.63,P=.004,Bonferroni校正)。结论提示HbA1c和CYP3A5基因型可能有助于理解肾移植6个月后他克莫司血药浓度的个体间和个体内变异。
要点
- CYP3A5非表达者他克莫司C/D比值高于表达者,且与HbA1c正相关。
- 肾移植6个月后,HbA1c升高与CYP3A5非表达状态共同影响他克莫司浓度。
- 男性性别是治疗6个月后他克莫司C/D比值升高的影响因素之一。
核心结论
- HbA1c和CYP3A5基因型可能有助于理解成人肾移植6个月后他克莫司血药浓度的个体间和个体内变异。
研究设计与样本
- 回顾性观察性队列研究,纳入42例年龄>18岁、口服控释他克莫司的肾移植受者。
- CYP3A5基因型分为表达者(*1/*1或*1/*3)和非表达者(*3/*3)。
- 采用多因素线性回归分析确定给药后7天、6个月和12个月他克莫司体重标化谷浓度/剂量比(C/D比值)的预测因素。
- 采用Bonferroni校正评估基线、他克莫司起始后6个月和12个月时C/D比值与HbA1c水平的相关性。
主要发现
- 42例患者中CYP3A5表达者17例,非表达者25例。
- 多因素线性回归显示,第7天C/D比值在CYP3A5非表达者中 marginally 高于表达者(r=.43,P=.028)。
- 影响治疗6个月后他克莫司C/D比值升高的因素为男性性别和CYP3A5非表达者(r=.59,P<.001)。
- 影响治疗12个月后他克莫司C/D比值升高的因素为HbA1c水平升高和CYP3A5非表达者(r=.62,P<.001)。
- CYP3A5非表达者中,12个月时C/D比值与HbA1c水平呈正相关(y=54.6x-194.6,r=.63,P=.004,Bonferroni校正);6至12个月C/D比值与HbA1c的个体内变化接近相关(y=54.5x+20.2,r=.41,P=.036,Bonferroni校正)。
临床怎么用
- 对于CYP3A5非表达者,肾移植6个月后监测HbA1c可能有助于预判他克莫司谷浓度的个体内变化。
- 临床解读他克莫司浓度时,可结合CYP3A5基因型和HbA1c水平综合评估个体间和个体内变异。
局限性
- 本研究为回顾性观察性队列研究,样本量较小(42例)。
- 原文未报告多中心验证或前瞻性干预数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Diabetes mellitus affects the pharmacokinetics of cytochrome P450 3A4/5 (CYP3A4/5) substrates. We evaluated the relationship between haemoglobin A1c (HbA1c) levels and the pharmacokinetics of controlled-release tacrolimus. METHODS: This retrospective observational cohort study included kidney transplant recipients (>18 years) receiving controlled-release tacrolimus orally. CYP3A5 genotypes were categorized as expressers (*1/*1 or *1/*3) and non-expressers (*3/*3). Multiple linear regression analysis determined the predictors for trough concentration/dose-normalized by body weight (C/D) ratio of tacrolimus at 7 days, 6 months and 12 months after administration. Correlations between the C/D ratio and HbA1c levels at baseline, 6 and 12 months after tacrolimus initiation were evaluated with Bonferroni correction. RESULTS: Out of 42 patients (CYP3A5 expressers, n = 17, and non-expressers, n = 25), the multiple linear regression analysis showed that the C/D ratio on Day 7 was marginally higher in CYP3A5 non-expressers than in CYP3A5 expressers (r = .43, P = .028). Factors affecting the elevation of tacrolimus C/D ratio after 6 and 12 months of treatment were male sex and CYP3A5 non-expressers (r = .59, P < .001) and increased HbA1c levels and CYP3A5 non-expressers (r = .62, P < .001), respectively. The C/D ratio and HbA1c levels after 12 months was positively correlated in CYP3A5 non-expressers (y = 54.6x - 194.6, r = .63, P = .004, Bonferroni correction). Furthermore, intra-individual changes in the C/D ratio and HbA1c levels from 6 to 12 months were nearly correlated (y = 54.5x + 20.2, r = .41, P = .036, Bonferroni correction). CONCLUSION: HbA1c and CYP3A5 genotypes might be considered to understand the inter- and intra-individual variability in blood tacrolimus concentrations after 6 months post-kidney transplantation.
引用
- Hirai T, Morikawa Y, Onishi R, et al. Impact of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation. Br J Clin Pharmacol. 2023. PMID: 36640105. doi:10.1111/bcp.15662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。